Clinical Trials Browser

Adenocarcinoma, Breast Neoplasms, Carcinoma, Renal Cell, Camurati-Engelmann Syndrome, Liver Neoplasms, Melanoma, Mesothelioma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

NCT04551950 2024-03-08

Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)

Phase 1 Completed

25 enrolled 14 charts

Gynecologic

Uterine Cervical Neoplasms, Camurati-Engelmann Syndrome

NCT04066491 2023-11-14

Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC

Phase 2/3 Terminated

309 enrolled 17 charts

Gastrointestinal

Biliary Tract Neoplasms, Camurati-Engelmann Syndrome, Gallbladder Neoplasms, Cholangiocarcinoma

NCT03833661 2023-10-25

M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)

Phase 2 Completed

159 enrolled 23 charts

Gastrointestinal

Biliary Tract Neoplasms, Camurati-Engelmann Syndrome, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04958434 2023-10-23

Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1 Terminated

19 enrolled

Camurati-Engelmann Syndrome, Neoplasms

NCT02178358 2022-02-25

A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma

Phase 2 Completed

132 enrolled 25 charts

Gastrointestinal

Camurati-Engelmann Syndrome, Carcinoma, Hepatocellular

NCT04158700 2020-02-19

A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer

Phase 1/2 Withdrawn

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Camurati-Engelmann Syndrome, Carcinoma, Hepatocellular

NCT02160106 2019-05-09

First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors

Phase 1 Completed

35 enrolled

Keratoacanthoma familial, Camurati-Engelmann Syndrome, Neoplasm Metastasis, Neoplasms

NCT00431561 2013-12-03

Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma

Phase 2 Completed

141 enrolled

CNS

Astrocytoma, Brain Neoplasms, Camurati-Engelmann Syndrome, Glioblastoma, Neoplasms